Amcenestrant, a once-promising investigational optimized oral selective estrogen receptor degrader (SERD) from Sanofi (Nasdaq: SNY), did not meet the primary endpoint in a recent Phase 2 trial focused on advanced or metastatic breast cancer.
Sanofi had previously referred to amcenestrant as a “potentially transformative” product.
Investigators did not identify any new safety signals for the drug candidate in the Phase 2 AMEERA-3 trial.
SNY initially dipped after the news was announced but had stabilized by the middle of the day — up 1.60% to $50.94.
Some 367 patients participated in the open-label study.
Sanofi plans to study amcenestrant in the upcoming AMEERA-5 and AMEERA-6 studies.
“This Phase 2 trial evaluated amcenestrant as a monotherapy in a patient population with advanced disease where limited treatment options remain,” said Dr. John Reed, head of research and development at Sanofi. “While we are disappointed with the AMEERA-3 results, we continue to investigate amcenestrant in patients with earlier stages of breast cancer with different tumor profiles and where different standard of care treatments are used.”
Filed Under: Oncology
